- Total cash, equivalents, and marketable securities stood at $78.6M as of September 30, 2026
- Topline results for Phase 2 ALTITUDE-AD study expected in November 2026
- Net loss of $78.8M for the first nine months of 2026 reflects continuous clinical cash burn
?? Negative AI Sentiment (-1.5 / 10)
Observed market reaction after signal
4h +3.28%